Azurity Pharmaceuticals completed the acquisition of Bowel Prep Franchise from Sebela.

Azurity Pharmaceuticals, a privately held company committed to delivering innovative, high-quality medicines for overlooked patients, completed the acquisition of Bowel Prep Franchise, including two leading bowel preparation therapies for colonoscopies, from Sebela, a pharmaceutical company. Financial terms were not disclosed. “We are pleased to welcome Sebela Pharmaceuticals’ GI team and product portfolio to Azurity. This strategic acquisition aligns with our long-term growth priorities by strengthening our presence in Gastroenterology and further diversifying our portfolio of medicines. We look forward to building on Sebela’s strong heritage of innovation in gastroenterology and continuing to deliver meaningful value to patients, healthcare providers, and our partners," Ronald Scarboro, Azurity Pharmaceuticals CEO.